vs
Side-by-side financial comparison of GERON CORP (GERN) and STEM, INC. (STEM). Click either name above to swap in a different company.
GERON CORP is the larger business by last-quarter revenue ($47.2M vs $47.1M, roughly 1.0× STEM, INC.). STEM, INC. runs the higher net margin — -33.9% vs -39.0%, a 5.1% gap on every dollar of revenue. On growth, GERON CORP posted the faster year-over-year revenue change (67.1% vs -15.6%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs 36.1%).
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
GERN vs STEM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $47.1M |
| Net Profit | $-18.4M | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | -29.4% | -17.7% |
| Net Margin | -39.0% | -33.9% |
| Revenue YoY | 67.1% | -15.6% |
| Net Profit YoY | 30.3% | 68.8% |
| EPS (diluted) | $-0.03 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.1M | ||
| Q3 25 | $47.2M | $38.2M | ||
| Q2 25 | $49.0M | $38.4M | ||
| Q1 25 | $39.6M | $32.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | $28.3M | $29.3M | ||
| Q2 24 | $882.0K | $34.0M | ||
| Q1 24 | $304.0K | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-18.4M | $-23.8M | ||
| Q2 25 | $-16.4M | $202.5M | ||
| Q1 25 | $-19.8M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $-26.4M | $-148.3M | ||
| Q2 24 | $-67.4M | $-582.3M | ||
| Q1 24 | $-55.4M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | — | -17.7% | ||
| Q3 25 | -29.4% | -33.6% | ||
| Q2 25 | -25.4% | -34.8% | ||
| Q1 25 | -42.2% | -65.0% | ||
| Q4 24 | — | -84.4% | ||
| Q3 24 | -99.8% | -493.2% | ||
| Q2 24 | -7860.9% | -1705.5% | ||
| Q1 24 | -18465.1% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -39.0% | -62.2% | ||
| Q2 25 | -33.4% | 527.8% | ||
| Q1 25 | -50.1% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | -93.5% | -506.3% | ||
| Q2 24 | -7639.8% | -1712.6% | ||
| Q1 24 | -18220.4% | -283.9% |
| Q4 25 | — | $-4.40 | ||
| Q3 25 | $-0.03 | $-2.84 | ||
| Q2 25 | $-0.02 | $-1.79 | ||
| Q1 25 | $-0.03 | $-0.15 | ||
| Q4 24 | — | $-15.29 | ||
| Q3 24 | $-0.04 | $-18.24 | ||
| Q2 24 | $-0.10 | $-71.81 | ||
| Q1 24 | $-0.09 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $248.7M | $-249.4M |
| Total Assets | $567.4M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $48.9M | ||
| Q3 25 | $78.1M | $43.1M | ||
| Q2 25 | $77.7M | $40.8M | ||
| Q1 25 | $83.7M | $58.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | $60.3M | $75.4M | ||
| Q2 24 | $116.9M | $89.6M | ||
| Q1 24 | $189.8M | $112.8M |
| Q4 25 | — | $-249.4M | ||
| Q3 25 | $248.7M | $-235.7M | ||
| Q2 25 | $259.5M | $-214.1M | ||
| Q1 25 | $268.2M | $-417.5M | ||
| Q4 24 | — | $-398.4M | ||
| Q3 24 | $292.3M | $-344.1M | ||
| Q2 24 | $306.7M | $-203.2M | ||
| Q1 24 | $344.9M | $371.6M |
| Q4 25 | — | $308.9M | ||
| Q3 25 | $567.4M | $362.6M | ||
| Q2 25 | $555.2M | $379.2M | ||
| Q1 25 | $562.5M | $405.1M | ||
| Q4 24 | — | $437.4M | ||
| Q3 24 | $444.9M | $537.8M | ||
| Q2 24 | $449.4M | $691.5M | ||
| Q1 24 | $482.1M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.6M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.2M | ||
| Q3 25 | $-13.6M | $11.4M | ||
| Q2 25 | $-27.4M | $-21.3M | ||
| Q1 25 | $-48.0M | $8.5M | ||
| Q4 24 | — | $-14.7M | ||
| Q3 24 | $-58.9M | $-9.4M | ||
| Q2 24 | $-53.5M | $-11.9M | ||
| Q1 24 | $-62.3M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-53.7M | — | ||
| Q1 24 | $-62.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6086.6% | — | ||
| Q1 24 | -20680.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 202.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
